
Centene Corporation
NYSE•CNC
CEO: Ms. Sarah M. London
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 2001-12-13
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
Contact Information
Centene Plaza, 7700 Forsyth Boulevard, Saint Louis, MO, 63105, United States
314-725-4477
Market Cap
$19.91B
P/E (TTM)
-3.8
46.4
Dividend Yield
--
52W High
$66.81
52W Low
$25.08
52W Range
Rank25Top 8.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$49.69B+18.25%
4-Quarter Trend
EPS
-$13.50-1085.40%
4-Quarter Trend
FCF
$1.15B-201.24%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Growth Strong Total revenues reached $49.7 B for Q3 2025, marking 18% growth versus prior year period.
Operational Efficiency Improves Q3 SG&A expense ratio improved to 7.0% from 8.3% last year, showing better cost leverage.
Adjusted Earnings Solid Adjusted diluted EPS was $0.50 for the quarter, compared to $1.62 in the third quarter 2024.
Cash Position Strengthened Cash, cash equivalents, and restricted cash ended at $17.185 B, increasing from year-end 2024.
Risk Factors
Goodwill Impairment Recorded Recorded $6.7 B goodwill impairment charge in Q3 2025, driving significant GAAP net loss.
Medical Cost Trend Worsening Q3 HBR rose to 92.7% from 89.2% due to increased Marketplace costs and IRA PDP changes.
Medicaid Membership Declining Total at-risk membership fell 672 K members to 27.968 M due to state redeterminations.
Debt Leverage Increased Debt-to-capital ratio rose to 45.5% from 41.2% due to equity reduction from goodwill charge.
Outlook
Medicare Star Ratings Improving Approximately 60% of Medicare Advantage membership now enrolled in 3.5 star or higher plans.
Commercial Rate Adjustments Planned Refiled 2026 Marketplace rates in Q3 2025 to reflect higher projected morbidity baseline.
Sufficient Liquidity Expected Available cash and credit facilities expected to finance operations and CapEx for at least 12 months.
Navigating Regulatory Changes Future results expected to be impacted by OBBBA provisions affecting Medicaid eligibility and funding.
Peer Comparison
Revenue (TTM)
CNC$185.86B
MOH$44.55B
FMS$21.68B
Gross Margin (Latest Quarter)
INCY92.8%
90.8%
87.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| WAT | $22.98B | 35.4 | 31.3% | 30.6% |
| UTHR | $22.66B | 17.5 | 18.8% | 0.0% |
| ILMN | $20.62B | 29.9 | 30.0% | 41.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.8%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 3, 2026
EPS:-$1.25
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 29, 2025|Revenue: $49.69B+18.2%|EPS: $-13.50-1085.4%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 25, 2025|Revenue: $48.74B+22.4%|EPS: $-0.51-123.6%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 25, 2025|Revenue: $46.62B+15.4%|EPS: $2.64+21.7%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 18, 2025|Revenue: $163.07B+5.9%|EPS: $6.33+27.4%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 25, 2024|Revenue: $42.02B+10.5%|EPS: $1.37+57.5%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 26, 2024|Revenue: $39.84B+5.9%|EPS: $2.16+11.9%MeetForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 26, 2024|Revenue: $40.41B+3.9%|EPS: $2.17+5.9%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 20, 2024|Revenue: $154.00B+6.5%|EPS: $4.97+137.8%Beat